RGNX REGENXBIO Inc.
$7.24▲ +9.70%
Healthcare
Other
After hours
$7.23▼ -0.18%
Oct 28, 6:01 PM ET
Volume 2.00M
Avg Volume (10D) 1.25M
Key Metrics & Fundamentals
Market Cap
$477.94M
P/E Ratio
–
Div Yield
0.00%
52W Range
5.46 - 16.19
% vs 50 MA
-11.19%
% vs 200 MA
-21.71%
RSI-14
46.8
MACD Histogram
+0.0200
Beta (1Y vs SPY)
1.78
Free Cash Flow
-$63.00M
Gross Rev
$108.02M
Gross Profit
$106.98M
EBITDA
$33.04M
COGS
$1.04M
Operating Exp
$77.71M
Operating Income
$29.26M
EBIT
$29.26M
Pretax Income
$22.71M
Net Income
$22.71M
EPS (Diluted)
0.43
Price & Volume History
Loading chart…
Recent News
Has The Story Under Krystal Biotech Stock Run Out?
Trefis · Oct 28, 2026 4:22 AM ET
REGENXBIO Eyes Q4 Pivotal Readout for One-Time Wet AMD Gene Therapy
MarketBeat · Oct 21, 2026 5:02 PM ET
REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20
PR Newswire · Oct 12, 2026 7:05 AM ET
Microsoft upgraded, HubSpot downgraded: Wall Street's top analyst calls
The Fly · Oct 5, 2026 9:44 AM ET
Regenxbio’s Two Lead Gene Therapies Back Mizuho’s Nearly 200% Upside Call
Stocktwits · Oct 5, 2026 7:42 AM ET
Mizuho Initiates REGENXBIO at Outperform With $22 Price Target
MT Newswires · Oct 5, 2026 6:02 AM ET
Regenxbio stock gains on positive gene therapy trial data
Investing.com · Sep 25, 2026 9:37 AM ET
REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting
PR Newswire · Sep 24, 2026 7:17 PM ET
Trump Administration Shift Puts This Corner of Biotech Back in Favor
The Wall Street Journal · Sep 16, 2026 5:30 AM ET
REGENXBIO to Participate in Upcoming Investor Conferences
PR Newswire · Sep 8, 2026 7:05 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See RGNX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.